Loading...
Adding Ibrutinib to Standard Therapy Reduces Disease Progression by 80% in Previously Treated Patients with CLL
Na minha lista:
| Udgivet i: | Am Health Drug Benefits |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Engage Healthcare Communications, LLC
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4570072/ https://ncbi.nlm.nih.gov/pubmed/26380625 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|